Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Gains from Investment Securities (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Gains from Investment Securities for 4 consecutive years, with -$1.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities fell 1222.56% to -$1.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $131899.0, a 17.05% increase, with the full-year FY2024 number at $9649.0, down 98.59% from a year prior.
  • Gains from Investment Securities was -$1.0 million for Q3 2025 at bioAffinity Technologies, down from $962552.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $2.0 million in Q2 2023 to a low of -$1.0 million in Q3 2025.
  • A 4-year average of $236338.9 and a median of $12560.0 in 2023 define the central range for Gains from Investment Securities.
  • Biggest YoY gain for Gains from Investment Securities was 17662.54% in 2025; the steepest drop was 1222.56% in 2025.
  • bioAffinity Technologies' Gains from Investment Securities stood at $7142.0 in 2022, then skyrocketed by 75.86% to $12560.0 in 2023, then skyrocketed by 624.82% to $91038.0 in 2024, then plummeted by 1222.56% to -$1.0 million in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Gains from Investment Securities are -$1.0 million (Q3 2025), $962552.0 (Q2 2025), and $100266.0 (Q1 2025).